CHARLES RIVER LABORATORIES INTERNATIONAL, INC.(CRL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,954 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CRL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRL at 43.8/100 on a 32-signal composite quality model, placing it at rank #1,954 of 2,961 stocks — the bottom half of the AI-ranked universe. CRL scores in the top quartile across earnings quality (86.4). Areas of concern include profitability (21.4) and revenue growth (21.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 42.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reports quarterly revenue of $1.0B, net income of $-1.5M, free cash flow of $148.6M. Top institutional holders of CRL by reported 13-F value include FMR, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CRL trades on the NYSE exchange and files with the SEC under CIK 1100682. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. directly from SEC EDGAR. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s 13F Pro composite quality score has ranged between 43 and 71 since 2021, currently 43.8 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.0B
Net Income
Q2 2026
$-1.5M
Free Cash Flow
Q2 2026
$148.6M
ROIC
Q2 2026
8.8%
D/E Ratio
Q2 2026
0.93
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-0.9% YoYNet Income
-750.1% YoYOperating Income
-88.9% YoYEPS (Diluted)
-1555.0% YoYTotal Assets
-5.2% YoYTotal Debt
-4.6% YoYOp. Cash Flow
+0.4% YoYFree Cash Flow
+3.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.02B -0.9% | $4.05B -1.9% | $4.13B +3.9% | $3.98B +12.3% | $3.54B +21.1% | $2.92B |
| Net Income | $-144.3M -750.1% | $22.2M -95.3% | $474.6M -2.4% | $486.2M +24.4% | $391.0M +7.3% | $364.3M |
| Operating Income | $25.2M -88.9% | $227.3M -63.2% | $617.3M -5.2% | $651.0M +10.4% | $589.9M +36.3% | $432.7M |
| EPS (Diluted) | $-2.91 -1555.0% | $0.20 -97.8% | $9.22 -2.7% | $9.48 +24.7% | $7.60 +5.6% | $7.20 |
| Total Assets | $7.14B -5.2% | $7.53B -8.1% | $8.20B +7.8% | $7.60B +8.2% | $7.02B +27.9% | $5.49B |
| Total Debt | $2.14B -4.6% | $2.24B -15.5% | $2.66B -2.1% | $2.71B +1.7% | $2.67B +31.5% | $2.03B |
| Operating Cash Flow | $737.6M +0.4% | $734.6M +7.4% | $683.9M +10.4% | $619.6M -18.6% | $760.8M +39.2% | $546.6M |
| Free Cash Flow | $518.5M +3.4% | $501.6M +37.3% | $365.4M +23.9% | $294.9M -44.6% | $532.0M +40.0% | $380.0M |
Get alerted when CRL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. including:
Top Institutional Holders of CRL
FMR LLC
$961.5M4,239,752 shBlackRock, Inc.
$861.5M3,798,560 shVANGUARD CAPITAL MANAGEMENT LLC
$714.2M3,149,288 shInvesco Ltd.
$676.9M2,984,785 shHARRIS ASSOCIATES L P
$508.3M2,241,144 shVANGUARD PORTFOLIO MANAGEMENT LLC
$501.4M2,210,979 shAllspring Global Investments Holdings, LLC
$436.5M1,905,247 shSTATE STREET CORP
$422.8M1,864,284 shDIMENSIONAL FUND ADVISORS LP
$373.8M1,648,450 shARIEL INVESTMENTS, LLC
$341.6M1,506,185 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $961.5M | 4,239,752 |
| BlackRock, Inc. | $861.5M | 3,798,560 |
| VANGUARD CAPITAL MANAGEMENT LLC | $714.2M | 3,149,288 |
| Invesco Ltd. | $676.9M | 2,984,785 |
| HARRIS ASSOCIATES L P | $508.3M | 2,241,144 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501.4M | 2,210,979 |
| Allspring Global Investments Holdings, LLC | $436.5M | 1,905,247 |
| STATE STREET CORP | $422.8M | 1,864,284 |
| DIMENSIONAL FUND ADVISORS LP | $373.8M | 1,648,450 |
| ARIEL INVESTMENTS, LLC | $341.6M | 1,506,185 |
Companies Similar to CRL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Elanco Animal Health Inc
Viatris Inc
COOPER COMPANIES, INC.
Fortrea Holdings Inc.
Teladoc Health, Inc.
PERRIGO Co plc
DENTSPLY SIRONA Inc.
Envista Holdings Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CRL on your watchlist
Track score changes the day CHARLES RIVER LABORATORIES INTERNATIONAL, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CRL a good stock to buy?
13F Pro's AI-powered analysis of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRL are available on the CRL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRL is classified as a large company.
Which hedge funds own CRL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s investment landscape.